光学相干断层扫描生物标志物用于Alport综合征及COL4相关FSGS的无创诊断
本研究评估OCT指标TTIMax对遗传性足细胞病的诊断价值。在93例经基因确诊的Alport综合征患者和136例对照中,TTIMax可区分疾病严重程度(重症AS 11.8%,中间型7.3-8.1%,对照5.3-5.8%),诊断重症AS的AUC为0.98,阈值8.4%时灵敏度93%、特异度99%,并可区分COL4相关FSGS与原发FSGS(AUC 0.91)。
要点
- TTIMax是一种无创OCT指标,可辅助诊断遗传性足细胞病。
- TTIMax诊断重症Alport综合征的AUC达0.98,阈值8.4%时灵敏度93%、特异度99%。
- TTIMax有助于区分COL4相关FSGS与原发免疫介导FSGS。
核心结论
- TTIMax是一种广泛可及的无创结构生物标志物,可补充基因检测,并可能辅助诊断遗传性足细胞病及解读COL4意义未明变异。
研究设计与样本
- 研究纳入93例经基因确诊的Alport综合征患者和136例对照(84例慢性肾脏病和52例健康个体),以基因诊断为参考标准,评估OCT衍生的TTIMax诊断性能。
主要发现
- TTIMax在不同基因型间分层疾病严重程度:重症X连锁AS男性/常染色体隐性AS为11.8%,中间型X连锁AS女性/常染色体显性AS为7.3-8.1%,对照为5.3-5.8%。
- 调整年龄、eGFR和血压后,TTIMax仍与疾病严重程度显著相关。
- ROC分析显示TTIMax对重症AS的判别力优异(AUC 0.98;95%CI 0.96-1.00),最佳阈值为8.4%(灵敏度93%,特异度99%)。
- TTIMax可区分重症AS与原发免疫介导的局灶节段性肾小球硬化(AUC 0.97;95%CI 0.94-1.00),并区分COL4A相关FSGS与原发FSGS(AUC 0.91;95%CI 0.77-1.00)。
- 纵向随访4-14年显示,尽管肾功能变化,TTIMax保持稳定。
关键数值与推荐
- 重症AS诊断阈值:TTIMax 8.4%,灵敏度93%,特异度99%,AUC 0.98(95%CI 0.96-1.00)。
- 区分重症AS与原发免疫介导FSGS的AUC为0.97(95%CI 0.94-1.00)。
- 区分COL4A相关FSGS与原发FSGS的AUC为0.91(95%CI 0.77-1.00)。
临床怎么用
- TTIMax可作为无创辅助工具,用于遗传性足细胞病的诊断及COL4变异解读,尤其适用于疑似Alport综合征或COL4相关FSGS患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Alport syndrome (AS) is a hereditary glomerulopathy often associated with ocular abnormalities, yet structural retinal biomarkers remain underutilized in nephrology. Here, we evaluated the Temporal Thinning Index Maximum (TTIMax), a subject-level optical coherence tomography (OCT) metric, as a potential diagnostic biomarker for inherited podocytopathies. METHODS: We evaluated TTIMax derived from OCT in 93 genetically confirmed patients with AS and 136 controls (84 with chronic kidney disease and 52 healthy individuals). Genetic diagnosis served as the reference standard and TTIMax as the index test. Diagnostic performance was assessed using receiver operating characteristic (ROC) analysis with calculation of sensitivity and specificity. RESULTS: TTIMax stratified disease severity across genotypes (severe X-linked AS-Male/autosomal recessive AS: 11.8%; intermediate X-linked AS-Female/autosomal dominant AS: 7.3-8.1%; controls: 5.3-5.8%) and remained significantly associated with disease severity after adjustment for age, eGFR, and blood pressure. ROC analysis demonstrated excellent discrimination for severe AS (area under the curve (AUC) 0.98; 95% Confidence Interval 0.96-1.00) with an optimal threshold of 8.4% (sensitivity 93%, specificity 99%). TTIMax distinguished severe AS from primary immune-mediated focal segmental glomerulosclerosis (FSGS) (AUC 0.97; 0.94-1.00) and differentiated COL4A-related FSGS from primary FSGS (AUC 0.91; 0.77-1.00). Longitudinal follow-up (four-14 years) demonstrated stability of TTIMax despite changes in kidney function. CONCLUSIONS: TTIMax provides a widely accessible, non-invasive structural biomarker that complements genetic testing and may aid in diagnosing inherited podocytopathies and interpreting COL4 variants of uncertain significance.
引用
- Ibrahim A, Kolachalama VB, Abuelsamen T, et al. Noninvasive optical coherence tomography biomarker for Alport syndrome, COL4-related focal segmental glomerulosclerosis, and COL4 variant interpretation. Kidney Int. 2026. PMID: 42498059. doi:10.1016/j.kint.2026.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。